novo-nordisk pharma insulin ozempic wegovy glp1 obesity denmark
related: Eli Lilly PhRMA AbbVie
Who They Are
Novo Nordisk A/S. Danish pharmaceutical company that has become the most valuable company in Europe (market capitalization: $400+ billion, 2024) primarily through its GLP-1 receptor agonist drugs — Ozempic (diabetes), Wegovy (weight loss), and their successors. Revenue: $33 billion (2024). Novo Nordisk is the world’s largest insulin producer and, alongside Eli Lilly, dominates the emerging obesity treatment market.
Novo Nordisk’s US political operation is managed through its American subsidiary. The company’s PAC contributes $1-2 million per cycle, with lobbying spending of $5-8 million annually. As a foreign-headquartered company, Novo Nordisk’s US political operation is constrained by FARA requirements, but the company’s market dominance in insulin and GLP-1 drugs gives it enormous regulatory leverage.
What They Want
Opposition to drug price negotiation expansion (particularly for GLP-1 drugs), favorable Medicare/Medicaid coverage for obesity treatment (creating a massive taxpayer-funded market), patent protection for GLP-1 biologics, reduced FDA approval requirements for indication expansion, and favorable PBM regulation that shifts blame for high drug prices from manufacturers to intermediaries.
What They’ve Gotten
GLP-1 Market Dominance: Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound have created a market projected to exceed $100 billion annually by 2030. The companies have successfully framed obesity as a medical condition requiring pharmaceutical treatment — rather than a systemic issue driven by food industry practices, economic stress, and sedentary work environments. This medicalization creates a permanent pharmaceutical revenue stream from a condition affecting 40%+ of Americans.
Insulin Oligopoly Preservation: Novo Nordisk, Eli Lilly, and Sanofi control 90% of the global insulin market. Despite insulin being discovered in 1921 (and the patent sold for $1), the three companies have maintained monopoly pricing through incremental patent modifications (“evergreening”), rebate agreements with PBMs, and regulatory barriers to biosimilar entry.
Money
The insulin pricing scandal is the pharmaceutical industry’s most damning case study. Insulin — discovered in 1921, patent sold for $1 because the inventors believed it should be universally accessible — costs $2-4 to manufacture per vial. Novo Nordisk, Lilly, and Sanofi charge $200-300 per vial in the US (versus $20-30 in most other countries). The pricing difference is entirely attributable to the US regulatory and patent framework that these three companies spend $20+ million annually lobbying to maintain. 8.4 million Americans depend on insulin; the three-company oligopoly extracts approximately $30 billion annually from this captive market.
Sources
- OpenSecrets: Novo Nordisk organizational profile (Tier 1)
- Senate Finance Committee: Insulin pricing investigation (Tier 1)
- FDA: Insulin product approvals and biosimilars (Tier 1)
- Ballotpedia: Novo Nordisk (Tier 3)
content-readiness:: ready